SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-060044
Filing Date
2023-03-03
Accepted
2023-03-03 16:14:39
Documents
12
Period of Report
2023-03-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d146910d8k.htm   iXBRL 8-K 24373
  Complete submission text file 0001193125-23-060044.txt   145866

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA qncx-20230301.xsd EX-101.SCH 2852
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE qncx-20230301_lab.xml EX-101.LAB 17993
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE qncx-20230301_pre.xml EX-101.PRE 11262
6 EXTRACTED XBRL INSTANCE DOCUMENT d146910d8k_htm.xml XML 3368
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38890 | Film No.: 23704114
SIC: 2836 Biological Products, (No Diagnostic Substances)